Abbott, Merck, Pfizer raising the bar

Share this article:
Abbott Labs stands out as a leader in marketing research, according to a panel discussion at CBI’s 2nd Annual Pharmaceutical Market Research Summit in Philadelphia at the end of April.

“Their business analysts are very personable and you end up with a tight delivery,” said Peter Simpson, president, Segmedica.

 “They are great at integrating information into what they do daily,” added John Tapper, chief strategy officer, Ziment.

Merck was among the large companies given the thumbs-up by the panel. “Merck is a great example of a company getting, and implementing, strategies in the entire space,” said Meredith Abreu, VP at Manhattan Research. “They are very good at getting information out there.”

Pfizer also drew praise. “The brands act like smaller companies,” said Simpson, “so when you go in you are reporting it your way.”

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.